Convergence of observations with other candidate therapies showing improvement in preclinical models of hyperinflammation LPS-ALI or bleomycin-ALI models via induction of neutrophil apoptosis, such as roscovitine (CDK2, 7, 9 inhibitor) (38)or AT7519 (39), and necrolysin (Nec-1, inhibitor of necroptosis) (40), provide further support for neutrophil-targeted therapeutic approaches. This evidence concerns the gene PCSK1 and acute respiratory distress syndrome.